Document is current
Any future updates will be listed below
-
Authors
Li, Che-Hsing https://orcid.org/0000-0003-0660-1125
Sharma, Sandhya
Heczey, Andras A. https://orcid.org/0000-0002-4263-9115
Woods, Mae L.
Steffin, David H. M.
Louis, Chrystal U.
Grilley, Bambi J.
Thakkar, Sachin G.
Wu, Mengfen
Wang, Tao https://orcid.org/0000-0003-1957-7160
Rooney, Cliona M.
Brenner, Malcolm K.
Heslop, Helen E. https://orcid.org/0000-0001-7049-7698
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (P30CA125123, P01CA094237, P01CA094237, P30CA125123, P30CA125123, P01CA094237, P01CA094237)
- License Information
-
More Information
Article History
Received: 7 April 2024
Accepted: 14 January 2025
First Online: 17 February 2025
Competing interests
: C.M.R., M.K.B. and H.E.H. are cofounders of and equity holders in AlloVir, Inc. and Marker Therapeutics. M.K.B. and C.M.R. have equity in March Biosciences and serve on advisory boards for March Biosciences, Marker Therapeutics, Allogene, Walking Fish, Abintus, Tessa Therapeutics, Athenex, Onk Therapeutics, Coya Therapeutics, Triumvira, Adaptimmune, Vor Therapeutics and TScan. H.E.H. has served on advisory boards for GlaxoSmithKline, Fresh Wind Biotechnologies, March Biosciences, Marker Therapeutics and Tessa Therapeutics and has share options in Co-Regen, Fresh Wind Biotechnologies and March Biosciences. B.J.G. owns QBRegulatory Consulting, which has agreements with March Biosciences. C.U.L. has equity in and is an employee of TScan. A.A.H. has consultancy/scientific advisory roles with Waypoint Bio, Dispatch Bio and Cargo Therapeutics. The other authors declare no competing financial interests.
